Post-Approval watch: tracking a rare cancer Drug's Real-World performance
NCT ID NCT07132567
Summary
This study is monitoring how safe and effective the drug Poteligeo (mogamulizumab) is for patients in Korea who are already using it to treat two rare types of skin lymphoma. It will follow about 15 adult patients who have tried at least one other treatment before. The goal is to collect real-world information on side effects and how well the drug works after it has been approved for use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chung-Ang University Hospital
TERMINATEDSeoul, South Korea
-
Ewha Womans University Mokdong Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kosin University Gospel Hospital
RECRUITINGBusan, Busan Metropolitan City, 49267, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.